Core Insights - Zylox-Tonbridge Medical Technology Co., Ltd. is focused on building a globally competitive vascular intervention platform through R&D-driven innovation and an expanding global commercial footprint [2][4]. Group 1: Company Strategy and Innovation - The company showcased a broad portfolio of commercialized and late-stage pipeline products, emphasizing its competitive edge in neurovascular and peripheral vascular indications [3]. - Key products include the intravascular optical coherence tomography (OCT) system and the ZYLOX Pantheris atherectomy catheter, which allows real-time visualization-guided plaque removal in peripheral arteries, marking a significant advancement in precision-based interventions [3][7]. - Zylox-Tonbridge's management highlighted the integration of product innovation, manufacturing industrialization, and global commercialization as essential for scaling the business [4]. Group 2: Growth and Market Expansion - By 2025, the cumulative use of Zylox-Tonbridge products exceeded one million procedures, indicating strong physician adoption of its technologies [4]. - The company established commercial coverage in 83 countries and regions by the end of 2025 and formed strategic partnerships with over 80 distributors and commercial partners worldwide [5]. - Zylox-Tonbridge aims to strengthen its global operating platform to support continued organic growth and selective external expansion in major international medtech markets [5]. Group 3: Company Overview - Zylox-Tonbridge, founded in 2012 and headquartered in Hangzhou, China, is dedicated to the innovative research, development, manufacturing, and commercialization of medical devices in the vascular intervention field [6]. - The company adheres to the brand philosophy of "Innovation for Quality Life," aiming to provide high-quality, affordable medical devices and services to improve patients' quality of life [8].